Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.64 EUR | -1.80% | -0.61% | +1.23% |
03-15 | Naturhouse Health, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Naturhouse Health, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company's attractive earnings multiples are brought to light by a P/E ratio at 9.65 for the current year.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- This company will be of major interest to investors in search of a high dividend stock.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
- For several months, analysts have been revising their EPS estimates roughly upwards.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's earnings growth outlook lacks momentum and is a weakness.
- Most analysts recommend that the stock should be sold or reduced.
Ratings chart - Surperformance
Sector: Other Specialty Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.23% | 105M | - | ||
+27.38% | 29.56B | A- | ||
+4.90% | 5.71B | B- | ||
-11.42% | 4.42B | C | ||
+14.25% | 4.17B | C+ | ||
+4.23% | 1.85B | - | B- | |
-4.59% | 1.77B | C+ | ||
-13.78% | 1.26B | - | C | |
-17.17% | 1.15B | B- | ||
-2.08% | 613M | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NTH Stock
- Ratings Naturhouse Health, S.A.